ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NUVB / earnings
KLRA (45) ANIP (63) STOK (46) QURE (38) ⌘ Pro Terminal →

Nuvation Bio Inc. (Class A) (NUVB) Next Earnings Date & Expected ±10% Move

$4.59 -3.57% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.55

Nuvation Bio Inc. (Class A) (NUVB) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.67B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NUVB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NUVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nuvation Bio Inc. (Class A) (NYSE: NUVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.59 (-3.57% 1D, market cap $1.67B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NUVB ranks #989 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NUVB compare to KLRA and ANIP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NUVB carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KLRA (Kailera Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.67B) and ANIP (ANI Pharmaceuticals Inc.) posts a C grade (63/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.65B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NUVB?
▼

Per NUVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001811063), Nuvation Bio Inc. (Class A) generated $62.9M in revenue (+699.0% YoY), -$204.6M in net income, and -$173.4M in free cash flow against $594.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.55 (-0.83%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510019
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (4)SEC (8)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.6% Base Target
$10 Bull$4 Base$3 Bear
📬 FREE NUVB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUVB)Realized 20D OHLCV Swing Band: ±10%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY NUVB SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (42% of score)

Altman Z-Score 0.76 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
27
Grade E$4.72+1.1% Next Q
Q2 (-2Q)
24
Grade E$4.77-4.6% Next Q
Q3 (-1Q)
22
Grade E$4.55+0.9% Next Q
Current
19
Grade E$4.59-12% Hist 90D α
Trajectory: E (27) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NUVB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NUVB currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.55) and Max Pain ($4.82) forces dealer call-delta covering toward $10.24.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NUVB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NUVB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 19%NO 81%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±10% Swing Band

±$0.46 Expected Swing
$4.13 (-10%)Spot $4.59$5.05 (+10%)
MODEL EARNINGS SETUP GAUGE

NUVB Quantitative Pre-Earnings Setup: 19/100

Trailing EPS: $4.25 • YoY Revenue Growth: 180%

Model Bullish Setup (19/100)Model Risk Weight (81/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$62.9M-$204.6M-$173.4M52%
FY 20242024-12-31$7.9M-$567.9M-$130.4M10.1%
FY 20232023-12-31$279.5M-$75.8M-$68.0M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NUVB)

  • ✓Walkthrough of NUVB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NUVB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.08%📐 HORIZONTAL RANGE
2026-11-03O $4.77H $4.77L $4.59C $4.59VOL 5.06M
RES: $8.91SUP: $4.20SMA50: $5.55SMA200: $5.39
$7.83$6.81$5.79$4.77$3.75RES $8.91SUP $4.20$4.592026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NUVB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NUVB Butterfly Map → + Track NUVB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +699.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NUVB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NUVB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NUVB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUVB)

Health Care Rank #989 of 1015 ⚔️ KLRA vs NUVB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NUVB vs. KLRA, ANIP, STOK, QURE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nuvation Bio Inc. (Class A) (NUVB) ranks #989 by composite RQD confidence (19/100, grade E) and #282 by equity capitalization ($1.67B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with NUVB at 19/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NUVB ACTIVE
Nuvation Bio Inc. (Class A)
E 19/100 — — -35.0% -3.57% $1.67B Benchmark Subject
KLRA
Kailera Therapeutics Inc.
D 45/100 — — — -5.52% $1.67B /klra-vs-nuvb →
ANIP
ANI Pharmaceuticals Inc.
C 63/100 21.5x — 16.0% -1.85% $1.65B /anip-vs-nuvb →
STOK
Stoke Therapeutics Inc.
D 46/100 — — -6.1% +0.72% $1.70B /stok-vs-nuvb →
QURE
uniQure N.V.
D- 38/100 — — -35.0% -7.49% $1.72B /qure-vs-nuvb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001811063 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuvation Bio Inc. (Class A) (NUVB) reported GAAP revenue of $62.9M (+699.0% vs. FY2024 revenue of $7.9M , and -77.5% cumulative change since FY2023) , GAAP net income of -$204.6M, operating cash flow of -$173.4M, and free cash flow of -$173.4M (-33.0% YoY). On the balance sheet, NUVB closed FY2025 with $594.8M in total assets against $0 in total debt (Altman Z-Score: 0.76, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $62.9M -$204.6M -$173.4M -$173.4M $594.8M —
FY2024 (FY) 2024-12-31 $7.9M -$567.9M -$130.4M -$130.4M $540.6M —
FY2023 (FY) 2023-12-31 $279.5M -$75.8M -$68.0M -$68.0M — —

3. NUVB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NUVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nuvation Bio Inc. (Class A) (NYSE: NUVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.59 (-3.57% 1D, market cap $1.67B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NUVB ranks #989 in composite RQD confidence.

How does NUVB compare to KLRA and ANIP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NUVB carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KLRA (Kailera Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.67B) and ANIP (ANI Pharmaceuticals Inc.) posts a C grade (63/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.65B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NUVB?

Per NUVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001811063), Nuvation Bio Inc. (Class A) generated $62.9M in revenue (+699.0% YoY), -$204.6M in net income, and -$173.4M in free cash flow against $594.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NUVB trading relative to its 50-day, 200-day, and 52-week technical levels?

NUVB last traded at $4.59 (-3.57% on volume of 3,723,554 shares), positioning the stock -17.30% below its 50-day simple moving average ($5.55) and -14.84% below its 200-day simple moving average ($5.39). Across its 52-week range of $3.92 to $9.75, NUVB sits at the 11.5% percentile with a 14-day RSI of 42.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.0% ($4.13 to $5.05).

Direct Sub-Reports: NUVB RQD Cockpit NUVB 12M Forecast NUVB Earnings & Move NUVB Dividends & DRIP NUVB Insiders & 13F NUVB Whale Options NUVB Profit Sankey NUVB News & Why
ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ SEC XBRL & RQD VERIFIED

NUVB — Nuvation Bio Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nuvation Bio Inc. (Class A) (NUVB) earns a live Roarable RQD composite score of 19/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.59 (-3.57% 1D, market capitalization $1.67B).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -10.35%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.76, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nuvation Bio Inc. (Class A) is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The company reports FY 2025 revenue of $62.9M which is a material increase from $7.9M in FY 2024..7B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nuvation Bio Inc. (Class A) (NUVB) reported $62.9M in annual revenue (up from $7.9M in FY2024, +699.0% YoY) and -$204.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($279.5M revenue, -$75.8M net income) through FY2025, NUVB scaled operating cash flow to -$173.4M and free cash flow to -$173.4M, backed by $594.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 19/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -10.35% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $3.92 – $9.75 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. An investor should note that the absence of graph data is a gap in the analysis, not evidence of an absence of dependencies. The sector (Health Care) and industry (Biotechnology: Pharmaceutical Preparations) classifications are the only structural context available.

  • Key Question #1: Can NUVB sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $62.9M and free cash flow of -$173.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NUVB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NUVB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nuvation Bio Inc. (Class A) (NUVB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NUVB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NUVB Bull vs. Bear Conversation Board — What's Your Call at $4.59?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NUVB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NUVB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $5.71 (+20.0%)
📌 Pinned Debate

Recent headlines reference a Phase III safusidenib milestone and a RBC-cited brain-cancer opportunity, and FY 2025 revenue rose to $62.

Long NUVB at $4.76 targeting $5.71. Recent headlines reference a Phase III safusidenib milestone and a RBC-cited brain-cancer opportunity, and FY 2025 revenue rose to $62.9M from $7.9M.. Institutional whale score is 4/20 and the risk/reward vs. the $3.92 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@CreditSpread_Watch Shorting a 4/20 institutional whale-flow stock at $4.76 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $3.62 (-23.9%)
Spot @ $4.76

ROIC of -35%, FCF yield of -10.35%, and an Altman Z-Score of 0.76 indicate the business is consuming capital and sits in a financial-di

Here is the bear case nobody on the bull side wants to address on NUVB: ROIC of -35%, FCF yield of -10.35%, and an Altman Z-Score of 0.76 indicate the business is consuming capital and sits in a financial-distress zone.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE